BIOMAT Database Logo BIOMAT Database Logo

Hypertension in diet versus pharmacologically treated diabetics: mortality over a 5-year follow-up. 1999

A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Cardiac Rehabilitation Institute and the Bezafibrate Infarction Prevention Coordinating Center, Neufeld Cardiac Research Institute, the Chaim Sheba Medical Center, Tel-Hashomer, Israel.

The natural history of non-insulin-dependent diabetes mellitus (NIDDM) differs markedly between patients with diet treated and pharmacologically treated disease. However, the interrelationship between hypertension and these common diabetes types has not been specifically addressed in previous studies. This study was designed to evaluate the prognostic significance and prevalence of hypertension in coronary patients with diet versus pharmacologically treated NIDDM over a 5-year follow-up period. The study sample comprised 11 515 patients aged 45 to 74 years with a previous myocardial infarction and/or anginal syndrome who had been screened but were not included in the Bezafibrate Infarction Prevention study. Among them, 9033 were nondiabetics and 2482, diabetics (987 diet treated and 1495 pharmacologically treated). The prevalence of hypertension among nondiabetics, diet-treated diabetics, and pharmacologically treated diabetics was 31%, 42%, and 43%, respectively. Crude all-cause mortality (CM) was lower in the nondiabetic patients (11.2% versus 22.0%; P<0.001). Among diabetics, 548 patients died: 81 diet treated normotensives (CM 14%); 100 diet-treated hypertensives (CM 24.4%); 205 pharmacologically treated normotensives (CM 24.2%); and 162 pharmacologically treated hypertensive patients (CM 25.0%). Age-adjusted mortality was lowest for the normotensive patients in the diet-treated group and highest for the hypertensive pharmacologically treated patients. Multivariate analysis shows that hypertension is a strong and independent predictor of increased CM in diet-treated but not in pharmacologically treated NIDDM: hazard ratio (HR) was 1.68 (95% confidence interval [CI] 1.24 to 2.29) for the diet-treated versus 1. 01 (95% CI 0.82 to 1.26) for the pharmacologically treated diabetics. The contribution of hypertension to stroke mortality was substantial for both diet treated and pharmacologically treated NIDDM: hazard ratios were 3.17 (95% CI 1.12 to 8.98) and 2.21 (95% CI 0.72 to 6.77), respectively. The increased risk of mortality associated with hypertension in relatively mild diet-treated NIDDM strongly supports the clinical benefit of early blood pressure control among diabetic patients with ischemic heart disease.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Mortality among patients treated for alcoholism: a 5-year follow-up.
September 1975, Canadian Medical Association journal,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
[Mortality and morbidity of treated arterial hypertension: a 7-year follow-up].
April 1984, Revista medica de Chile,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Mortality of Japanese diabetics in a seven-year follow-up study.
June 1986, Diabetes research and clinical practice,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Mortality among treated alcoholics. A three year follow-up study.
September 1959, Quarterly journal of studies on alcohol,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
[Indicators of follow-up activities undertaken by an arterial hypertension unit over a 5 year period].
September 1993, Atencion primaria,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
October 1994, HNO,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Emotion suppression and mortality risk over a 12-year follow-up.
October 2013, Journal of psychosomatic research,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Arthroscopic Versus Open Ankle Arthrodesis: A 5-Year Follow Up.
July 2022, The Journal of bone and joint surgery. American volume,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction.
January 1988, Acta medica Scandinavica,
A Tenenbaum, and E Z Fisman, and V Boyko, and U Goldbourt, and E Graff, and J Shemesh, and A Shotan, and H Reicher-Reiss, and S Behar, and M Motro
Educational level and 5-year all-cause mortality in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group.
June 1987, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!